KYMR VS SNDX Stock Comparison

Performance

KYMR
10/100

KYMR returned -38.95% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

SNDX
10/100

SNDX returned -33.90% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Sentiment

KYMR
69/100

KYMR had a bullish sentiment score of 68.98% across Twitter and StockTwits over the last 12 months. It had an average of 2.55 posts, 2.33 comments, and 0.61 likes per day.

SNDX
74/100

SNDX had a bullish sentiment score of 73.61% across Twitter and StockTwits over the last 12 months. It had an average of 5.00 posts, 1.29 comments, and 3.63 likes per day.

Technicals

KYMR
75/100

KYMR receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

SNDX
64/100

SNDX receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

Earnings

KYMR
10/100

KYMR has missed earnings 11 times in the last 20 quarters.

SNDX
57/100

SNDX has missed earnings 4 times in the last 20 quarters.

Profit

KYMR
10/100

Out of the last 17 quarters, KYMR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

SNDX
10/100

Out of the last 20 quarters, SNDX has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

KYMR
47/100

KYMR has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

SNDX
42/100

SNDX has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

Analyst Price Targets

KYMR

"Analyst Price Targets" not found for KYMR

SNDX
88/100

8 analysts offer 12-month price targets for SNDX. Together, they have an average target of 37.67, the most optimistic target put SNDX at 41 within 12-months and the most pessimistic has SNDX at 33.

All score calculations are broken down here to help you make more informed investing decisions

Kymera Therapeutics, Inc. Common Stock Summary

Nasdaq / KYMR

Healthcare

Biotechnology

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Syndax Pharmaceuticals, Inc. Summary

Nasdaq / SNDX

Healthcare

Biotechnology

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Power up your portfolio